Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Acoramidis (Primary)
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions; Registrational
- Acronyms ATTRibute-CM
- Sponsors Eidos Therapeutics
- 07 Apr 2024 According to a BridgeBio Pharma media release, the company submitted an MAA to the European Medicines Agency, with a decision expected in 2025.
- 07 Apr 2024 According to a BridgeBio Pharma media release, data from this study presented at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo
- 07 Apr 2024 Results from the exploratory CMR imaging substudy of ATTRibute-CM published in the BridgeBio Pharma Media Release